GuidelineJournal of thrombosis and haemostasis : JTH2016
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
Guideline in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- Comparative Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Morbidly Obese Patients (BMI \>40 kg/m2): A Systematic Review and Meta-Analysis.Current vascular pharmacology · 2025Pooled it
- SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Pooled it
- Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.Cardiovascular drugs and therapy · 2024Pooled it
- Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis.BMC cardiovascular disorders · 2023Pooled it
- Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.Clinical pharmacokinetics · 2022Pooled it
- Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review.Journal of thrombosis and thrombolysis · 2022Pooled it
- Obesity as a Risk Factor for Venous Thromboembolism Recurrence: A Systematic Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review.Clinical drug investigation · 2021Pooled it
- Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.Current oncology (Toronto, Ont.) · 2018Pooled it
- Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Implementation and Validation of the 2013 Caprini Score for Risk Stratification of Arthroplasty Patients in the Prevention of Venous Thrombosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Dabigatran use and cerebrovascular event risk across body mass index in atrial fibrillation: a real-world nested case-control study.Journal of thrombosis and thrombolysis · 2026Article
- The "obesity paradox" in dosing: a comprehensive analytical review of cockcroft-gault versus CKD-EPI for predicting clearance of narrow-therapeutic-index drugs in patients with BMI > 40 kg/m².European journal of clinical pharmacology · 2026Review
- Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis.Obesity surgery · 2026Article
- A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.Research and practice in thrombosis and haemostasis · 2026Review
- Efficacy and safety of direct oral anticoagulants and low molecular weight heparin for cancer-associated venous thromboembolism in patients with extremes in bodyweight.Journal of thrombosis and thrombolysis · 2026Article
- Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature.Cancers · 2026Review
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.